Data from Incyte’s Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings
Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from clinical trials of medicines that are being developed in-house and through partnerships with Novartis, MorphoSys and Takeda will be presented at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31); and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14).
“We are pleased to have virtual platforms such as ASCO20 and EHA25 to continue sharing important data with the scientific community in a timely manner,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “These data demonstrate the strength of our broad oncology portfolio and our partnerships; and reinforce our commitment to finding solutions that can help meet patients’ needs.”
Key abstracts accepted by ASCO and EHA include:
Oral, poster discussion and poster sessions, as well as track-based clinical science symposia, accepted for presentation at ASCO will be available on demand beginning Friday, May 29, 2020, 8:00 AM ET.
Capmatinib in Patients with High-Level MET-Amplified Advanced Non-Small Cell Lung Cancer (NSCLC): Results from the Phase 2 GEOMETRY mono-1 Study(Abstract #9509, Session: MET Mutations: The Meat of the Matter)1
Interim Analysis (IA) of OPTIC: A Dose-Ranging Study of Three Ponatinib (PON) Starting Doses (Abstract #7502, Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant)2
An Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib (PON) Phase 2 PACE Trial (NCT01207440) in Patients (pts) with Ph+ Leukemia (Abstract #7550, Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant)2
Re-MIND Study: A Propensity Score-Based 1:1 Matched Comparison of Tafasitamab + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) (Abstract #8020, Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia)3
Safety and Efficacy of Pemigatinib Plus Pembrolizumab Combination Therapy in Patients (pts) with Advanced Malignancies: Results from FIGHT-101, an Open-Label Phase 1/2 study (Abstract #3606, Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology)
Capmatinib in Patients with METex14-Mutated or High-Level MET-Amplified Advanced Non-Small-Cell Lung Cancer (NSCLC): Results from Cohort 6 of the Phase 2 GEOMETRY mono-1 study (Abstract #9520, Session: Lung Cancer—Non-Small Cell Metastatic)1
Pan-Cancer Analysis of FGFR1-3 Genomic Alterations to Reveal a Complex Molecular Landscape (Abstract #3620, Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology)
Oral abstract presentations and e-posters accepted for presentation at EHA will be available on the on-demand Virtual Congress platform beginning Friday, June 12, 2020, at 8:30 AM CEST.
Addition of Parsaclisib, a PI3Kδ inhibitor, in Patients with Suboptimal Response to Ruxolitinib (Rux): A Phase 2 Study in Patients (Pts) with Myelofibrosis (MF) (Abstract #S216, Session: Novel Therapies and Pitfalls in MPN)
Ruxolitinib Versus Best Available Therapy in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: Overall Response Rate by Baseline Characteristics in the Randomized Phase 3 REACH2 Trial (Abstract #S255, Session: Stem Cell Transplantation – Clinical: Graft-Versus-Host Disease)1
GRAVITAS-301: A Randomized, Double-Blind Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids for Initial Treatment of Patients with Acute Graft-Versus-Host Disease (Abstract #S256, Session: Stem Cell Transplantation – Clinical: Graft-Versus-Host Disease)
Interim Analysis from the OPTIC Trial, a Dose-Ranging Study of 3 Starting Doses of Ponatinib (Abstract #S172, Session: Chronic Myeloid Leukemia (CML) Clinical)2
Re-MIND Study: Comparison of Tafasitamab + Lenalidomide (L-Mind) vs Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Abstract #S238, Aggressive Lymphomas: Observational Studies)3
Real-World Survival in Elderly Patients with Myelofibrosis in the United States: Ruxolitinib Exposed vs Unexposed (Abstract #EP1124, Session: Myeloproliferative Neoplasms – Clinical)
Real-World Survival in Elderly Patients with Myelofibrosis in the United States: Pre- vs Post-Ruxolitinib Approval (Abstract # EP1120, Session: Myeloproliferative Neoplasms – Clinical)
Machine-Learning to Predict Hydroxyurea (HU) Failure and Incidence of Thromboembolic Events (TEs) with HU vs Ruxolitinib Switch Therapy in Polycythemia Vera Patients (Abstract #EP1117, Session: Myeloproliferative Neoplasms – Clinical)1
Patient-Reported Physical, Emotional and Economic Impact of Myeloproliferative Neoplasms in an Expansion of the MPN Landmark Survey (Abstract #EP1112, Session: Myeloproliferative Neoplasms – Clinical)1
Ruxolitinib in PV Patients Resistant and/or Intolerant to Hydroxyurea: Interim Analysis of a European Multi-Centric Observational Study (Abstract #EP1115, Session: Myeloproliferative Neoplasms – Clinical)1
Treatment and Disease Management Practices in Patients with MPNs in 6 Countries: An Expansion of the MPN Landmark Survey (Abstract #EP1123, Session: Myeloproliferative Neoplasms – Clinical)1
Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Phase 2 PACE Trial of Ponatinib in Philadelphia Chromosome Positive (Ph+) Leukemia (Abstract #EP759, Session: Chronic Myeloid Leukemia (CML) Clinical)2
The Real–Life Study Evaluating the Efficacy and Safety of Ponatinib “Topase” Reveals Induction of Deep Molecular Responses in a Cohort of 75 TKI-Resistant or Intolerant patients with CML (Abstract #EP765, Session: Chronic Myeloid Leukemia (CML) Clinical)
Combination of Tafasitamab (MOR208) and Lenalidomide Enhances Tumor Cell Death of B-cell Lymphoma in Vitro (Abstract #EP1343, Session: Lymphoma Biology & Translational Research)3
Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (Mor208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Abstract #EP1201, Session: Aggressive Non-Hodgkin Lymphoma - Clinical)3
Expression of CD19 Antigen on Chronic Lymphocytic Leukemia Cells After Tafasitamab (Anti-CD19) Treatment: Phase I Trial Data (Abstract #EP671, Chronic Lymphocytic Leukemia and Related Disorders - Biology & Translational Research)3
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s or partner company’s ongoing clinical development pipeline, and whether or when any development compounds will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, its presentation plans for the upcoming ASCO and EHA meetings and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the Company’s dependence on its relationships with its collaboration partners; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ended March 31, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.
1Novartis-sponsored; 2Takeda-sponsored; 3MorphoSys-sponsored
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor’s WICOP Bi-color LEDs Are Shining in the Headlamp of Audi A4 Model Year 202022.9.2020 11:11:00 CEST | Press release
Seoul Semiconductor Co., Ltd. (“Seoul”) (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that it has supplied WICOP Bi-color (2 colors in one package) LED products for the daytime running lights and front turn signals of the 2020 Audi A4 (B9 facelift) headlamp. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005448/en/ 2020 Audi A4 with Seoul Semiconductor’s WICOP Bi-Color LEDs (Source: Audi) This is the first example of Seoul Semiconductor's WICOP product being mounted on an Audi headlamp. WICOP Bi-color LED is a core patented technology of Seoul Semiconductor that realizes both white and yellow in one package. It is designed to directly mount the LED chip on the board without an additional package. “Due to the narrow space between the light emitting surfaces of the Bi-color LED, it is technically beneficial to light up one cavity with yellow for turn and white for DRL. This advanta
Medis Selects Veeva CRM to Deliver Personalized Experiences to Healthcare Professionals22.9.2020 10:00:00 CEST | Press release
Veeva Systems (NYSE:VEEV) today announced that Medis has switched to multichannel Veeva CRM in 15 countries across Central and Eastern Europe to advance its commercial strategy and drive more efficient and effective interactions with healthcare professionals (HCPs). “Veeva CRM gives our teams a flexible solution that adapts to the unique go to market strategies of every customer,” said Kristina Jerič, multichannel implementation lead at Medis. “Now, our field teams can get the customer insights they need to quickly drive targeted, relevant interactions with HCPs.” Medis is a leading independent medical marketing company that specializes in the commercialization of innovative pharmaceutical products. The company needed a CRM solution to effectively execute their customers’ commercial and medical strategies with speed and compliance. With Veeva CRM, Medis can now efficiently deliver compliant, tailored experiences to HCPs across all channels, including face-to-face, email, and web. “Veev
Veeva Commercial Cloud Selected by Idorsia to Accelerate Digital Engagement Globally22.9.2020 10:00:00 CEST | Press release
Veeva Systems(NYSE: VEEV) today announced that Idorsia Pharmaceuticals Ltd (SIX: IDIA) has selected Veeva Commercial Cloud to enable its digital field force in the U.S., Japan, and countries across Europe. Idorsia is at the forefront of innovative therapies and needed best-in-class cloud technology to drive its global commercial strategy. Veeva Commercial Cloud brings together multichannel engagement, data, content, and analytics to give Idorsia the foundation for digital excellence. “Veeva is an important partner that has helped us to rapidly scale-up, supporting our growth plans,” said Joseph Bejjani, CIO at Idorsia. “Veeva Commercial Cloud streamlines commercial processes from pre-launch planning to execution and digitally enables our field force to more effectively engage customers.” Adoption of Veeva Commercial Cloud builds upon Idorsia’s success with Veeva Development Cloud in speeding end-to-end product development. Idorsia is a fast-growing biopharmaceutical company based in Sw
CGTN: China Makes Proposals for UN's Role in Post-Pandemic Era22.9.2020 08:48:00 CEST | Press release
The United Nations, beginning with 51 signatories at the end of World War II, has now grown to be a 193-nation body. As it celebrates its 75th founding anniversary, the organization and multilateralism it represents are facing unprecedented challenges with the rise of unilateralism and protectionism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005948/en/ The challenges are being compounded by COVID-19, which has infected more than 31 million people and taken over 960,000 lives worldwide. "What kind of UN does the world need and what role should it play in the post-pandemic era?" Chinese President Xi Jinping raised the question and made proposals on Monday when addressing the high-level meeting to commemorate the 75th anniversary of the UN via video link. The UN should uphold justice as countries, regardless of their sizes, are equal and should respect each other, Xi said, noting that this is a requirement of the pro
inwi money Launches International Money Transfer Capability in Partnership With WorldRemit and MFS Africa22.9.2020 08:00:00 CEST | Press release
inwi money, a subsidiary of inwi and leading telecom player in mobile money services, has expanded its offering with the launch of an international money transfer service for its “inwi money” customers. “The launch of this new service is a concrete result of our efforts to diversify the available payment methods in Morocco, to widen financial inclusion to encompass a greater number of Moroccans and to reduce dependency on cash transactions. inwi customers can now receive money from their loved ones abroad quickly and securely”, explains Nicolas Levi, CEO of inwi money. How does it work? Once the money transfer is authorised by the sender via the WorldRemit platform, the recipient is notified by SMS, and the transferred amount is directly credited to their inwi money account. This new service is the result of a strategic partnership between inwi money and WorldRemit, a leading provider of online money transfer services, as well as MFS Africa, a leading Pan-African fintech which operates
ASICS Supports Tennis Coaching Community With New Virtual Academy22.9.2020 07:30:00 CEST | Press release
ASICS EMEA today announced the launch of the ASICS TENNIS ACADEMY, a virtual community platform that gives tennis coaches access to advice and training from industry experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005789/en/ Introducing ASICS Tennis Academy, a virtual platform to support and empower tennis coaches everywhere. (Photo: Business Wire) Independent research* shows that 90% of tennis players rely on their coach for advice and recommendations about how to improve their game. However, most coaches say they lack the time and resources to stay informed, while also coaching full-time. Based on the specific needs of coaches, ASICS has created the Tennis Academy to provide easy access to the information they need. Experts, including elite coaches, strength trainers, physiotherapists and sports psychologists will share bespoke training videos and articles, so coaches have the latest trends and training infor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom